Novavax boosts 2026 revenue forecast as licensing deals pay off
NVAX•NVAX•NVAX•NVAX•Novavax raised its 2026 adjusted revenue forecast to $385 million-$415 million from $235 million-$275 million, above analysts’ average estimate of $380.29 million. It reported a third-quarter net loss of $31 million, compared with $202 million a year earlier.
Novavax said it expects 2026 adjusted revenue of $385 million to $415 million, up from its previous forecast of $235 million to $275 million and above analysts’ average estimate of $380.29 million. The company is relying on payments tied to licensing deals and partnerships involving its vaccine platform and Matrix-M adjuvant.
Novavax is betting on its licensing agreement with Sanofi, worth at least $1.2 billion, to reach profitability by 2028. Sanofi plans a late-stage U.S. trial in 2027 of an influenza-COVID-19 combination vaccine using Novavax’s Nuvaxovid; Novavax is eligible for a $225 million milestone payment upon U.S. commercial launch. Novavax reported a quarterly net loss of $31 million, compared with $202 million a year earlier.
